CorMedix surged 59% since March, driven by strong DefenCath sales and its acquisition of Melinta Therapeutics, diversifying its portfolio. DefenCath's robust Q1 and Q2 sell-in exceeded expectations, ...
The Central and Eastern Europe Fund, Inc. remains attractive with low portfolio P/E of 8.58x and 12% earnings yield. Read why CEE CEF is a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback